3CPA DAA Project by University of Queensland 2006‌ Sample Clauses

3CPA DAA Project by University of Queensland 2006‌. Quality Medication Care Pty Ltd, in conjunction with the University of Queensland, evaluated the effectiveness and cost-effectiveness of DAAs in the community and residential care facility (RCF) settings. The project, which developed preliminary best practice models for both settings, was funded as part of the 3CPA between the Commonwealth and the Pharmacy Guild of Australia. The Phase 3 Final Report (May 2006) recommended that the preliminary best practice model for the community setting, and the findings of the evaluation, should be used to inform the development of, and implementation plan for a subsidised DAA service for community patients. Further, the 2006 Final Report recommended that the government supports the use of DAA services in the community where patients meet the appropriate access criteria and the service provided reflects best practice. The project was composed of three phases: • Phase 1 (Final Report November 2004) involved a synthesis of the literature that expanded and updated an earlier review of the literature on DAAs (conducted by the University of South Australia in 1997), taking into account national and international literature published from 1997 to December 2002. Focus groups and structured interviews were also conducted with stakeholders in Phase 1 to identify key issues. • Phase 2 (Final Report November 2004) involved recruitment of pharmacies, residential care facilities and consumers, and the development of data collection instruments. Observation studies were conducted in the community and RCF settings. The goal of observation in the community setting was to examine what impact using a DAA has on the consumers’ lifestyle, and to observe the procedures (time and cost) involved for community pharmacy in supplying DAAs to domiciliary consumers. • Phase 3 (Final Report May 2006) involved the development of best practice models and tools to facilitate improvements in the way DAAs are used in the RCF and community settings. This was based on the DAA literature review (Phase 1); current practice and standards of DAA provision (Phase 2); views of stakeholders obtained through focus groups and structured interviews; consensus development panel techniques; consultation with the Therapeutic Goods Administration (TGA); and evaluation of the feasibility and impact of best practice models. The cost-effectiveness of DAAs was then again examined in the community setting by measuring and valuing the benefits to the health care system from ...